Rise Nano Optics Lists on Canadian Exchange with Seven-Patent Nanotech Lenses for Q1 2026 Launch
Rise Nano Optics begins trading today on the Canadian Securities Exchange under symbol EYE, backed by FDA Class I exempt registration and plans for North American commercialization in Q1 2026. Its SPECTRAGUARD™ nanotech lenses, protected by seven patents, filter up to 90% of high-energy visible wavelengths (400–600nm) in a market projected to grow from US$161 billion in 2025 to US$267 billion by 2034.
1. CSE Listing Launch
Rise Nano Optics commenced trading on the Canadian Securities Exchange under symbol EYE on March 12, 2026, marking its debut as a publicly listed company with approved common share listings.
2. Proprietary SPECTRAGUARD Technology
The company’s SPECTRAGUARD™ lens treatments employ nanotechnology to filter up to 90% of wavelengths between 400 and 600 nm while preserving natural colour and contrast, and its IP portfolio includes seven patents covering materials, production methods and lens architecture.
3. Commercialization Strategy and Market Opportunity
Following FDA Class I exempt classification and biocompatibility testing, Rise is set to begin North American commercialization in Q1 2026 through partnerships with optical labs, direct-to-consumer brands and strategic lab acquisitions, targeting a global eyewear market expected to expand from US$161 billion in 2025 to US$267 billion by 2034.